½ÃÀ庸°í¼­
»óǰÄÚµå
1592051

Å©¶óº£º´ Ä¡·á ½ÃÀå : Áúȯ À¯Çü, Ä¡·á¹ý, À¯Åë ä³Îº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Krabbe Disease Treatment Market by Disease Type (Infantile, Late-onset), Treatment (Anticonvulsant Agents, Bone Marrow Transplantation, Muscle Relaxer Drugs), Distribution Channel - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 192 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Å©¶óº£º´ Ä¡·á ½ÃÀåÀº 2023³â¿¡ 17¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â¿¡´Â 18¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 6.49%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 26¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Å©·¡ºêº£º´Àº ½Å°æ°è¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Èñ±ÍÇϰí Á¾Á¾ Ä¡¸íÀûÀÎ À¯Àü ÁúȯÀ¸·Î, º¹À⼺°ú Á¦ÇÑµÈ Ä¡·á ¿É¼ÇÀ¸·Î ÀÎÇØ Á¡Á¡ ´õ ¸¹Àº ÀÇ·á ¿¬±¸ÀÇ ÃÊÁ¡ÀÌ µÇ°í ÀÖ½À´Ï´Ù. Ä¡·á¹ýÀº ÁÖ·Î Á¶Ç÷¸ð¼¼Æ÷À̽Ä(HSCT), È¿¼Ò´ëü¿ä¹ý, À¯ÀüÀÚ Ä¡·á µîÀÌ ÀÖÁö¸¸, ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ È¿°ú¿Í °¡¿ë¼ºÀÌ Á¦ÇÑÀûÀ̱⠶§¹®¿¡ ½ÃÀå ¼ö¿ä´Â ¿©ÀüÈ÷ ³ôÀº ÀÓº£µðµå´Ï´Ù. ÀÌ·¯ÇÑ ¹ÌÃæÁ· ¼ö¿ä¿Í »ý¸í°øÇÐ ¹× ÀǾàǰÀÇ ¹ßÀüÀÌ ¸Â¹°·Á º¸´Ù È¿°úÀûÀ̰í Á¢±ÙÇϱ⠽¬¿î ¼Ö·ç¼Ç °³¹ß¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â Áúº´¿¡ ´ëÇÑ Àνİú Áø´Ü Áõ°¡, À¯ÀüÀÚ ¿¬±¸ÀÇ ¹ßÀü, Èñ±ÍÁúȯ¿¡ ´ëÇÑ Á¤ºÎÀÇ Áö¿ø Á¤Ã¥ µîÀÌ ÀÖ½À´Ï´Ù. ÃֽŠºñÁî´Ï½º ±âȸ´Â CRISPR°ú °°Àº À¯ÀüÀÚ ÆíÁý ±â¼ú°ú »õ·Î¿î ¾à¹° Á¦Á¦ÀÇ ¹ßÀüÀ¸·Î ȹ±âÀûÀÎ Ä¡·á¿Í ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖ´Â ÀáÀç·ÂÀ» Á¦°øÇÕ´Ï´Ù. ÇÏÁö¸¸ ÀÌ ½ÃÀåÀº ³ôÀº ¿¬±¸°³¹ßºñ¿ë, Èñ±ÍÁúȯ °ü·Ã ±ÔÁ¦ÀÇ º¹À⼺, Á¦ÇÑµÈ È¯ÀÚ Ç® µî ¿©·¯ °¡Áö Á¦¾à¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦¾àÀ» ±Øº¹Çϱâ À§ÇØ ±â¾÷Àº °øµ¿ ¿¬±¸ ±¸»ó°ú Çмú±â°ü°úÀÇ Á¦ÈÞ¿¡ ÁýÁßÇÒ ¼ö ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·áÀÇ Çõ½Å, ƯÈ÷ À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏ¿¡ µû¸¥ ¸ÂÃãÇü Ä¡·á´Â ÀáÀçÀûÀÎ ¼ºÀå°ú Â÷º°È­¸¦ °¡Á®´Ù ÁÙ ¼ö ÀÖ´Â Èï¹Ì·Î¿î ºÐ¾ßÀÔ´Ï´Ù. ½ÃÀåÀÇ Æ¯¼ºÀº ¿©ÀüÈ÷ µµÀüÀûÀ̸鼭µµ À¯¸ÁÇϸç, ±Þ¼ÓÇÑ ±â¼ú ¹ßÀü°ú ´õºÒ¾î ¹°·ù ¹× ÀçÁ¤Àû À庮ÀÌ ³ô´Ù´Â Ư¡ÀÌ ÀÖ½À´Ï´Ù. ¼º°øÀûÀÎ ½ÃÀå ÁøÀÔ°ú ¸®´õ½ÊÀ» È®º¸Çϱâ À§Çؼ­´Â R&D¿¡ ´ëÇÑ Àü·«Àû ÅõÀÚ, »õ·Î¿î ±ÔÁ¦ ¿ä°Ç¿¡ ´ëÇÑ ¹ÎøÇÑ ´ëÀÀ, ±×¸®°í Áß¿äÇÑ ¹ÌÃæÁ· ¼ö¿ä¿¡ ´ëÇÑ Àü¹®Àû ´ëÀÀÀ» À§ÇÑ ÆäÀ̽¼Æ® ¿©Á¤¿¡ ´ëÇÑ È®½ÇÇÑ ÀÌÇØ°¡ ÇÊ¿äÇÕ´Ï´Ù. ±â¼ú µ¿Çâ, Á¤Ã¥ º¯È­, °æÀï»ç ¿òÁ÷ÀÓÀ» ¸ð´ÏÅ͸µÇϱâ À§ÇÑ Áö¼ÓÀûÀÎ ½ÃÀå Á¶»ç´Â Å©¶óº£º´ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×°ú Áö¼ÓÀûÀÎ ¼ºÀå¿¡ ÇʼöÀûÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ[2023³â] 17¾ï 2,000¸¸ ´Þ·¯
¿¹Ãø³â[2024³â] 18¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø³â[2030³â] 26¾ï 8,000¸¸ ´Þ·¯
CAGR(%) 6.49%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â Å©¶óº£º´ Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Å©¶óº£º´ Ä¡·áÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¿ªÀû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Àü ¼¼°è Å©¶óº£º´ À¯º´·ü Áõ°¡
    • À¯ÀüÀÚ Ä¡·á ¹× Áٱ⼼Æ÷ ÀÌ½Ä ¿¬±¸ Áõ°¡
    • À¯Àü¼º Áúȯ¿¡ ´ëÇÑ ÀÎ½Ä °³¼±À» À§ÇÑ Á¤ºÎ¿Í ¹Î°£ÀÇ ³ë·Â
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Å©¶óº£º´ Ä¡·á¿¡ µû¸¥ °íºñ¿ë
  • ½ÃÀå ±âȸ
    • Å©¶óº£º´ÀÇ Áø´Ü ¹× Ä¡·áÀÇ Áøº¸
    • Å©¶óº£º´ ¿¬±¸ È®´ë¸¦ À§ÇÑ À¯¸®ÇÑ ÀÚ±Ý »óȲ
  • ½ÃÀå °úÁ¦
    • Å©¶óº£º´ °Ë»ç ¹× Ä¡·á¿¡ °üÇÑ À±¸®Àû ¹®Á¦

Porter's Five Forces: Å©¶óº£º´ Ä¡·áÁ¦ ½ÃÀå °ø·«À» À§ÇÑ Àü·« Åø

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â µ¥ Áß¿äÇÑ ÅøÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀïÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ¸ð»öÇϱâ À§ÇÑ ¸íÈ®ÇÑ ¹æ¹ýÀ» ¼³¸íÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» º¸¿ÏÇϰí, ÀáÀçÀû µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Å©¶óº£º´ Ä¡·áÁ¦ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Å©¶óº£º´ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ ´ã°í ÀÖÀ¸¸ç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀ̰í Àû±ØÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : Å©¶óº£º´ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

Ŭ·¹º£º´ Ä¡·áÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ¼¼ºÐÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, À̸¦ ÅëÇØ °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º: Å©¶óº£º´ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Å©¶óº£º´ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ: Å©¶óº£º´ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ ¼º°øÀ¸·Î °¡´Â ±æ Â÷Æ®

Ŭ·¹º£º´ Ä¡·áÁ¦ ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÎ¹®¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÎ¹®ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» ±â¼úÇϰí ÀÖ½À´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, »ê¾÷ÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚµéÀÌ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ µµ¿òÀÌ µÇ´Â Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÔ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå Å©¶óº£º´ Ä¡·á ½ÃÀå : Áúȯ À¯Çüº°

  • ¼­·Ð
  • À¯¾Æ±â
  • ÈĹ߼º

Á¦7Àå Å©¶óº£º´ Ä¡·á ½ÃÀå : Ä¡·áº°

  • ¼­·Ð
  • Ç×°æ·Ã¾à
  • °ñ¼ö À̽Ä
  • ±ÙÀ̿Ͼà

Á¦8Àå Å©¶óº£º´ Ä¡·á ½ÃÀå : À¯Åë ä³Îº°

  • ¼­·Ð
  • E-Commerce
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ Å©¶óº£º´ Ä¡·á ½ÃÀå

  • ¼­·Ð
  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÅ©¶óº£º´ Ä¡·á ½ÃÀå

  • ¼­·Ð
  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Å©¶óº£º´ Ä¡·á ½ÃÀå

  • ¼­·Ð
  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023 ¸Å³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • Acorda Therapeutics Inc.
  • Apteeus SAS
  • Centogene N.V.
  • Forge Biologics, Inc.
  • Gain Therapeutics, Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • M6P Therapeutics
  • Neurogene Inc.
  • Novartis AG
  • Pfizer Inc.
  • Polaryx Therapeutics, Inc
  • Polpharma
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharmaceuticals
KSA 24.11.27

The Krabbe Disease Treatment Market was valued at USD 1.72 billion in 2023, expected to reach USD 1.83 billion in 2024, and is projected to grow at a CAGR of 6.49%, to USD 2.68 billion by 2030.

Krabbe Disease, a rare and often fatal genetic disorder affecting the nervous system, is increasingly becoming a focal point in healthcare research due to its complexity and limited treatment options. The treatment landscape primarily involves the application of hematopoietic stem-cell transplantation (HSCT), enzyme replacement therapies, and gene therapies, yet the market necessity remains high due to the limited efficacy and availability of these treatments. This unmet need, combined with advancements in biotech and pharmaceuticals, has sparked interest in the development of more effective and accessible solutions. Key growth influencers include increasing awareness and diagnosis of the disease, advances in genetic research, and supportive government policies aimed at rare diseases. Latest opportunities lie in the progression of gene-editing technologies like CRISPR and novel drug formulations, providing potential for groundbreaking treatments and improved quality of life for patients. Nevertheless, the market faces significant challenges, including high R&D costs, regulatory complexities associated with rare diseases, and a limited patient pool, which can deter investment. To overcome these limitations, businesses can focus on collaborative research initiatives and partnerships with academic institutions, which can provide access to cutting-edge technology and shared resources. Innovative efforts in personalized medicine, particularly in tailoring treatments based on genetic profiles, represent an exciting area of potential growth and differentiation. The nature of the market remains both challenging and promising, characterized by rapid technological advances alongside logistical and financial hurdles. Successful market entries and leadership would likely require strategic investment in R&D, agile adaptation to emerging regulatory requirements, and a robust understanding of the patient journey to address critical unmet needs expertly. Engaging in continuous market research to monitor technological trends, policy shifts, and competitive movements will be essential for positioning and sustaining growth in the Krabbe Disease treatment market.

KEY MARKET STATISTICS
Base Year [2023] USD 1.72 billion
Estimated Year [2024] USD 1.83 billion
Forecast Year [2030] USD 2.68 billion
CAGR (%) 6.49%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Krabbe Disease Treatment Market

The Krabbe Disease Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of Krabbe disease worldwide
    • Rise in gene therapy and stem cell transplantation research
    • Government and private initiatives to raise awareness about inherited disorders
  • Market Restraints
    • High cost associated with treatment for Krabbe disease
  • Market Opportunities
    • Advancements in the diagnosis and treatment of Krabbe disease
    • Favorable funding landscape for expanding research on krabbe disease
  • Market Challenges
    • Ethical issues with testing and treatment for Krabbe disease

Porter's Five Forces: A Strategic Tool for Navigating the Krabbe Disease Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Krabbe Disease Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Krabbe Disease Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Krabbe Disease Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Krabbe Disease Treatment Market

A detailed market share analysis in the Krabbe Disease Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Krabbe Disease Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Krabbe Disease Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Krabbe Disease Treatment Market

A strategic analysis of the Krabbe Disease Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Krabbe Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Acorda Therapeutics Inc., Apteeus SAS, Centogene N.V., Forge Biologics, Inc., Gain Therapeutics, Inc., GlaxoSmithKline Plc, Johnson & Johnson, M6P Therapeutics, Neurogene Inc., Novartis AG, Pfizer Inc., Polaryx Therapeutics, Inc, Polpharma, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and UCB Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Krabbe Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Infantile and Late-onset.
  • Based on Treatment, market is studied across Anticonvulsant Agents, Bone Marrow Transplantation, and Muscle Relaxer Drugs.
  • Based on Distribution Channel, market is studied across E-commerce, Hospital Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of Krabbe disease worldwide
      • 5.1.1.2. Rise in gene therapy and stem cell transplantation research
      • 5.1.1.3. Government and private initiatives to raise awareness about inherited disorders
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with treatment for Krabbe disease
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in the diagnosis and treatment of Krabbe disease
      • 5.1.3.2. Favorable funding landscape for expanding research on krabbe disease
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical issues with testing and treatment for Krabbe disease
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Krabbe Disease Treatment Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Infantile
  • 6.3. Late-onset

7. Krabbe Disease Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Anticonvulsant Agents
  • 7.3. Bone Marrow Transplantation
  • 7.4. Muscle Relaxer Drugs

8. Krabbe Disease Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. E-commerce
  • 8.3. Hospital Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Krabbe Disease Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Krabbe Disease Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Krabbe Disease Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Acorda Therapeutics Inc.
  • 3. Apteeus SAS
  • 4. Centogene N.V.
  • 5. Forge Biologics, Inc.
  • 6. Gain Therapeutics, Inc.
  • 7. GlaxoSmithKline Plc
  • 8. Johnson & Johnson
  • 9. M6P Therapeutics
  • 10. Neurogene Inc.
  • 11. Novartis AG
  • 12. Pfizer Inc.
  • 13. Polaryx Therapeutics, Inc
  • 14. Polpharma
  • 15. Sanofi S.A.
  • 16. Takeda Pharmaceutical Company Limited
  • 17. Teva Pharmaceutical Industries Ltd.
  • 18. UCB Pharmaceuticals
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦